MONROVIA, Calif.--(BUSINESS WIRE)--Prolacta Bioscience, a privately held company that provides the only commercially available human milk fortifier made exclusively from human milk for infants in the neonatal intensive care unit (NICU), announced today that it has secured over $12 million in funding, and that it has named former Baxter Bioscience President John Bacich as Chairman of the Board. Alta Partners led the financing and was joined by DFJ Frontier, Arcturus Capital, DFJ Mercury, Funk Ventures, Phillip Capital, Gideon Hixon Fund, and Draper Associates L.P., as well as others. Alison de Bord, Director at Alta Partners, joined the board of Prolacta in connection with the financing.
